Profile: Vermillion Inc (VRML.A)
5 Apr 2019
Vermillion, Inc., incorporated on May 23, 2000, is a diagnostic service and bio-analytic solutions provider. The Company is engaged in the business of developing and commercializing diagnostic tests for gynecologic disease. The Company sells OVA1 risk of malignancy test for pelvic mass disease (OVA1). The Company's OVA1 is a blood test designed to, in addition to a physician's clinical assessment of a woman with a pelvic mass, identify women who are at risk of having a malignant ovarian tumor prior to planned surgery. The Company developed OVA1 through pre-clinical studies in collaboration with various academic medical centers encompassing over 2,500 clinical samples. OVA1 is validated in a multi-center clinical trial encompassing approximately 30 sites reflective of the diverse nature of the clinical centers, at which ovarian adnexal masses are evaluated.
The Company's ASPiRA LABS is a laboratory that specializes in applying biomarker-based technologies to address critical needs in the management of gynecologic cancers and specifically pelvic mass disease. ASPiRA LABS provides diagnostic services using a biomarker-based diagnostic algorithm to inform clinical decision making and personalized treatment plans. The lab processes its OVA1 test. The Company focuses on expanding the testing provided by ASPiRA LABS to other gynecologic conditions with unmet need. It also focuses on developing and performing laboratory development tests (LDTs) at ASPiRA LABS.
The Company competes with Fujirebio Diagnostics, Becton Dickinson, ArrayIt Corporation and Abbott Laboratories.
12117 Bee Caves Road Building Th
AUSTIN TX 78738